Google
GLSI — GREENWICH LIFESCIENCES INC (Healthcare >> Biotechnology)
GLSI FAQ
What is GLSI's ROE?
GREENWICH LIFESCIENCES INC reports a Return on Equity (ROE) of -412.83%.
What is GLSI's dividend yield?
GREENWICH LIFESCIENCES INC offers a dividend yield of 0.00%.
What is GLSI's Deepscope Quality Score?
Deepscope rates GLSI's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy GLSI?
Deepscope's AI Timing Score for GLSI is 29 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does GLSI belong to?
GREENWICH LIFESCIENCES INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 23.88
Price
0.11
(0.46%)
Day Change
|
|
|---|
GLSI, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 58 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 23.88 |
| PBV / Sector |
65.20 / 4.95
|
| Earning Per Share | -1.51 |
| PE / Sector |
N/A / 18.38
|
| PEG or PE/Growth / Sector |
N/A / 0.62
|
| Average 1M Daily Value |
3.55 M
GREAT
|
| Average 1W Daily Value |
2.12 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-17 09:51:06 |
| Symbol | GLSI |
| Name | GREENWICH LIFESCIENCES INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 14.68 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 343.62 / 9,028.40 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Building 14, Stafford, TX, United States, 77477
Phone: 832-819-3232
Website: https://greenwichlifesciences.com
Sector: Healthcare >> Biotechnology
Description: Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
